The study by researchers in Australia also reveals the role of beta-amyloid precursor protein (APP), which forms plaques in affected brains.
What does BAPP stand for?
BAPP stands for Beta-Amyloid Precursor Protein
This definition appears somewhat frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of BAPP
We have 13 other meanings of BAPP in our Acronym Attic
- Business Aviation Professionals of New England
- Base Army Post Office (UK)
- Belgian Association of Pediatric Orthopaedics
- Belize Association of Producers Organization
- British Army Post Office
- British Association for Paediatric Otolaryngology
- British Association of Prosthetists and Orthotists
- Bay Area Probe Owners Club (Ford Probe owners; northern California)
- Bacteremia-Associated Pneumococcal Pneumonia (infectious diseases)
- Baltic-American Partnership Program
- Building As Power Plant (building with self generating energy technology)
- Bundesinitiative Ambulante Psychiatrische Pflege (German: Federal Initiative Outpatient Psychiatric Nursing Association)
- Business Account Package Policy (insurance)
- Bachelor of Applied Computing
- Badan Perencana Pembangunan Daerah (Indonesian: Regional body for planning and development)
- Badan Perencanaan Pembangunan Nasional (National Development Planning Agency Republic of Indonesia)
- Bay Area Pollution Prevention Group (California)
- Board for the Advancement of Psychology in the Public Interest
- Bachelor of Applied Information Systems
- Bachelor of Applied Science
Samples in periodicals archive:
Beta-Secretase (BACE-1) has been identified as a key enzyme that mediates a critical step in the formation of Beta-amyloid (ABeta40/42) by acting upon the Beta-amyloid precursor protein (Beta-APP).
While the mice given the beta-amyloid injections suffered no obvious ill effects, scientists caution that the shots could trigger an autoimmune response to the beta-amyloid precursor protein, which is present throughout the body.
Posiphen appears to modify the metabolism of beta-amyloid precursor protein (beta-APP).
Posiphen(TM) Posiphen has been shown to lower beta-amyloid precursor protein (beta -APP) levels in pre-clinical studies.
The Phase IIB trial seeks to evaluate the potential ability of Phenserine to lower the levels of beta-amyloid precursor protein ((beta)-APP) and beta-amyloid (A(beta)) levels in the plasma and cerebrospinal fluid (CSF) in AD patients following six (6) months of treatment.
Lymphocytes of AD patients are impaired in their proliferative response to metabolic products of Beta-amyloid Precursor protein (APP).
Phenserine is currently undergoing testing in a Phase IIB trial to evaluate its anticipated ability to lower levels of beta-amyloid precursor protein ((beta)-APP) and beta-amyloid (A(beta)) in the plasma and cerebrospinal fluid (CSF), which may lead to a slowing of disease progression.